Jung, MoonSun
Poltavets, Valentina
Skhinas, Joanna N
Tax, Gabor https://orcid.org/0000-0003-4530-0798
Kamili, Alvin https://orcid.org/0000-0002-4864-1195
Xie, Jinhan
Ghamrawi, Sarah
Graber, Philipp https://orcid.org/0000-0002-3157-1434
Mao, Jie https://orcid.org/0009-0009-6428-7788
Wong-Erasmus, Marie
Cui, Louise https://orcid.org/0000-0003-4762-3099
Kimpton, Kathleen https://orcid.org/0000-0002-9752-7022
Venkat, Pooja
Mayoh, Chelsea https://orcid.org/0000-0002-6398-3046
Lin, Angela https://orcid.org/0000-0002-2637-3070
Fleuren, Emmy D G
Fordham, Ashleigh M
Barger, Zara
Grady, John https://orcid.org/0000-0001-9667-3872
Thomas, David M
Du, Eric Y
Graf, Nicole S https://orcid.org/0000-0003-3608-2071
Cowley, Mark J https://orcid.org/0000-0002-9519-5714
Gifford, Andrew J https://orcid.org/0000-0002-4092-2347
Fletcher, Jamie I https://orcid.org/0000-0003-2949-9469
Lau, Loretta M S
Dolman, M Emmy M
Gooding, J Justin https://orcid.org/0000-0002-5398-0597
Kavallaris, Maria https://orcid.org/0000-0003-2309-898X
Funding for this research was provided by:
Federal Government | DHAC | National Health and Medical Research Council (2016464, 1196648, 2019056)
CCA | Cancer Council NSW (2020797)
Federal Government | DHAC | Cancer Australia (1185313)
Article History
Received: 13 August 2025
Revised: 2 September 2025
Accepted: 9 September 2025
First Online: 1 October 2025
Disclosure and competing interests statement
: MK and JJG hold options with Inventia Life Science Pty. Ltd. MK and JJG are co-inventors of a patent (WO2017/011854) related to the bioprinting technology used in this study. JIF receives an annual payment related to the development of venetoclax from the Walter and Eliza Hall Institute's distribution of royalties scheme.